Format

Send to

Choose Destination
Ann N Y Acad Sci. 2003 Nov;1003:318-27.

Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.

Author information

1
McLean Hospital, Belmont, Massachusetts 02478, USA. joseph_coyle@hms.harvard.edu

Abstract

Numerous clinical studies demonstrate that subanesthetic doses of dissociative anesthetics, which are noncompetitive antagonists at the NMDA receptor, replicate in normal subjects the cognitive impairments, negative symptoms, and brain functional abnormalities of schizophrenia. Postmortem and genetic studies have identified several abnormalities associated with schizophrenia that would interfere with the activation of the glycine modulatory site on the NMDA receptor. Placebo-controlled clinical trials with agents that directly or indirectly activate the glycine modulatory site consistently reduce negative symptoms and frequently improve cognition in patients with chronic schizophrenia who are receiving concurrent typical antipsychotics. Thus, there is convincing evidence that hypofunction of a subset of NMDA receptors may contribute to the symptomatic features of schizophrenia.

PMID:
14684455
DOI:
10.1196/annals.1300.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center